Sarcatinib, a Src/Fyn inhibitor, has been similarly shown to reduce tau pathology and microglial activation in transgenic AD mice, resulting in improved behavioral outcomes (Kaufman et al., 2015). The gene discussed is MAPT; the disease is Alzheimer disease.